|
Abstract Objective：To study the efficacy of Roxithromycin Sustained Release Capsulesin（RSRC） in treating stable Chronic Obstructive Pulmonary Disease（COPD） patients.Method：Totally 113 patients with stable COPD were randomly divided into the treatment group and the control group. All the patients were treated with basic therapy（including oxygen,eliminating phlegm to smooth wheezing,immune regulation,support treatment and health education）.The treatment group in the basic therapy combined with RSRC 0.15 g,1/d oral for 6 months.Dyspnea score,pulmonary function（FEV1/ FVC）,6-MWT,the quality of life（QOL） and the times of exacerbations were observed.Result：The indicators of FEV1/ FVC（%）,6-MWT and QOL were higher than those before the treatment（P<0.05）.The times of exacerbations and dyspnea score were smaller than those before the treatment（P<0.05）.The indicators of FEV1/FVC（%）,6-MWT and QOL in the treatment group were higher than those in the control group after the treatment（P<0.05）.The times of exacerbations and dyspnea score in the treatment group were smaller than those in the control group after the treatment （P<0.05）.Conclusion：Long-term treatment for stable COPD patients with RSRC is an effective means in relieving dyspnea,improving pulmonary function and QOL and preventing recurrence.
|
|
|
|
|
|
